Top Markets
Coin of the day
D. Western Therapeutics Institute, Inc. D. Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute, Inc.

4576
Classificação em ações #27419
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused... D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
Preço da ação
$0.57414457
Valor de mercado
$33.00M
Variação (1 dia)
4.76%
Variação (1 ano)
-23.09%
País
JP
Negociar D. Western Therapeutics Institute, Inc. (4576)

Categoria

EPS de D. Western Therapeutics Institute, Inc. (4576)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da D. Western Therapeutics Institute, Inc., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da D. Western Therapeutics Institute, Inc. de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
$17.32 -
US
$-7.98 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH